Verify any claim · lenz.io
Claim analyzed
Health“Creatine supplementation improves brain fog in humans.”
Submitted by Vicky
The conclusion
Open in workbench →Creatine may help some cognitive functions linked to what people call brain fog, but the evidence does not directly show that it generally improves “brain fog” in humans. Most studies measured objective cognitive tasks, not the symptom itself, and positive effects are most apparent in specific settings such as sleep deprivation, older adults, or other higher-demand conditions. The broad, unqualified wording goes beyond the evidence.
Caveats
- “Brain fog” was generally not a direct trial endpoint; the evidence is mostly indirect from cognitive test performance and fatigue-related measures.
- Effects are context-dependent and not consistently shown in healthy, well-rested adults; results vary by population, dose, and study design.
- A regulatory review did not support a general cognition claim at low daily doses, so dose and use case materially affect how the evidence should be interpreted.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
This systematic review and meta-analysis of randomized controlled trials included sixteen RCTs involving 492 participants aged 20.8–76.4 years, including healthy individuals and patients with specific diseases. Creatine supplementation showed significant positive effects on memory (SMD = 0.31, 95% CI: 0.18–0.44) and attention time, as well as significantly improving processing speed time. However, no significant improvements were found on overall cognitive function or executive function. The authors conclude: "Current evidence suggests that creatine monohydrate supplementation may confer beneficial effects on cognitive function in adults, particularly in the domains of memory, attention time, and information processing speed," while calling for larger robust clinical trials.
The United Kingdom Nutrition and Health Claims Committee (UKNHCC) evaluated evidence for creatine and cognition. In section 4.2 the committee states: "the committee concludes that a cause-and-effect relationship has not been established between the consumption of ≤3 g per day creatine and improved cognitive function." Earlier they cite a trial titled "Creatine supplementation does not improve cognitive function in young adults" and, after weighing the evidence, reiterate that for the dose levels commonly used for health claims in foods, the data do not substantiate a causal claim of improved cognitive function.
The rationale states that "Sleep deprivation has a negative effect on cognitive and psychomotor performance and mood state, partially due to decreases in creatine levels in the brain. Therefore, creatine supplementation should lessen the negative effects of sleep deprivation." The double‑blind study gave subjects either creatine monohydrate (5 g four times a day for 7 days) or placebo and then kept them awake for 24 hours with intermittent exercise. The authors report: "At 24 h, the creatine group demonstrated significantly less change in performance from 0 h (delta) in [random movement generation], choice reaction time, balance and mood state" compared with placebo, and conclude that "Following 24‑h sleep deprivation, creatine supplementation had a positive effect on mood state and tasks that place a heavy stress on the prefrontal cortex."
In this 2024 meta-analysis of creatine monohydrate supplementation on cognitive outcomes, the authors report: "Creatine supplementation showed significant positive effects on memory...and attention time...as well as significantly improving processing speed time." However, they also state that "no significant improvements were found on overall cognitive function or executive function." The GRADE assessment indicates "moderate" certainty of evidence for memory, but low certainty for processing speed, overall cognitive function, executive function, and attention, and the authors stress that larger robust clinical trials are needed to further validate these findings.
This systematic review searched multiple databases for randomized clinical trials examining the cognitive effects of oral creatine supplementation in healthy individuals and identified six studies (281 individuals). The authors report: "Generally, there was evidence that short term memory and intelligence/reasoning may be improved by creatine administration." For other domains, including long-term memory, attention, executive function, reaction time and mental fatigue, "the results were conflicting" and "performance on cognitive tasks stayed unchanged in young individuals." They conclude that oral creatine administration "may improve short-term memory and intelligence/reasoning" but its effect on other cognitive domains remains unclear, and that creatine may have a selective positive effect in aging and stressed individuals.
In this randomized, placebo-controlled crossover study, healthy adults underwent total sleep deprivation and received a single high oral dose of creatine or placebo. The authors report that "three hours after creatine intake, a positive effect on brain metabolism and cognitive performance was observed" and that the effect "peaked after 4 h and lasted up to 9 h." Improvements were seen particularly in "processing capacity and short-term memory" during sleep deprivation. They conclude that "a single but high dose of creatine enhances thinking capacity and causes changes in the brain's energy reserves during sleep deprivation," indicating an acute cognitive benefit under fatigue-like conditions.
This narrative review summarizes evidence that oral creatine can increase brain creatine stores and may influence cognitive outcomes. The authors note that creatine supplementation "can increase brain creatine stores, which may help explain some of the positive effects on measures of cognition and memory" reported in human studies. They discuss data showing cognitive benefits primarily under conditions of stress (such as sleep deprivation, hypoxia, or neurodegenerative disease) and in older adults, while emphasizing that findings across cognitive domains are mixed and that more high-quality clinical trials are needed.
This open-label pilot study assessed creatine in patients with traumatic brain injury (TBI) experiencing depression and fatigue. Participants received creatine monohydrate (5 g/day) for 6 months. The authors report that creatine was associated with significant improvements in measures of depression and "fatigue" and note trends toward better cognitive performance in some tests, suggesting a potential role of creatine in ameliorating fatigue-related symptoms in brain-injured patients. However, the uncontrolled design and small sample limit firm conclusions.
In this double‑blind crossover study, healthy volunteers received acute oral creatine loading (20 g/day for 7 days) or placebo, followed by 31P‑MRS and cognitive testing. The authors report that creatine supplementation "significantly increased brain creatine and phosphocreatine levels" and that this was accompanied by "improved performance in a complex cognitive task" compared to placebo. Although the participants were not sleep‑deprived, the authors interpret the data as evidence that raising brain creatine can enhance performance under high cognitive demand, which is relevant to conditions described by participants as mental fatigue.
This randomized, double‑blind, placebo‑controlled study investigated whether creatine supplementation (5 g three times daily for 7 days) could counteract the effects of 24 hours of sleep deprivation. The authors found that creatine "attenuated the increase in subjective fatigue" and preserved some aspects of cognitive performance, reporting that participants receiving creatine showed less impairment in attention and reaction time tasks than those on placebo after sleep loss. They also observed changes in cortical excitability measures consistent with creatine supporting brain energy metabolism under sleep deprivation.
This randomized, double‑blind, placebo‑controlled parallel‑group study assessed the effects of creatine on cognitive performance in elderly subjects (average age ~76 years). Participants received creatine supplementation or placebo for one week and completed a battery of cognitive tasks. The authors report that creatine‑treated participants showed significant improvements on long‑term memory tasks and measures of intelligence compared with placebo. They interpret these findings as evidence that creatine supplementation "has the potential to improve some aspects of cognitive functioning in the elderly."
In this 8-week open-label trial, female adolescents with SSRI-resistant major depressive disorder received oral creatine (2–4 g/day). The study found significant improvement in depression scores and reported reductions in fatigue-related symptoms. Neuroimaging showed increased brain phosphocreatine levels. While not focused on "brain fog" per se, the study provides preliminary evidence that creatine can modify brain energy metabolism and may help with mood and fatigue symptoms that are often associated with perceived cognitive clouding in depressed patients.
This double-blind, placebo-controlled, crossover trial examined the effects of 6 weeks of creatine supplementation on cognitive function in vegetarian adults. The authors report that creatine supplementation "had a significant positive effect on working memory" and on "intelligence" as measured by Raven's Advanced Progressive Matrices. They suggest that these effects reflect improved brain energy availability. The study did not measure "brain fog" directly but demonstrates that creatine can improve specific cognitive domains in certain subgroups (vegetarians) under controlled conditions.
Although focused on chronic diseases, this systematic review and meta‑analysis summarizes evidence that creatine can influence subjective fatigue. The authors note that across various conditions, creatine supplementation was associated with "small but significant reductions in self‑reported fatigue" in several trials, while others showed no clear benefit. They emphasize heterogeneity in dosing and populations, and conclude that creatine "may alleviate fatigue in some chronic conditions," but that more targeted trials are needed.
Although focused primarily on muscle outcomes, this systematic review and meta‑analysis of creatine supplementation in older adults includes discussion of cognitive measures from included RCTs. The authors note that some trials in older adults have reported improvements in cognitive tasks such as memory and intelligence with creatine compared to placebo, but that cognitive outcomes were not consistently assessed across studies and the overall evidence for cognition remains limited. They call for more well‑designed RCTs specifically targeting cognitive endpoints in older populations.
This medically oriented article summarizes several human trials on creatine under sleep deprivation or restriction. It describes a Journal of Psychopharmacology study where healthy volunteers underwent 24 hours of sleep deprivation and those taking 5 g creatine monohydrate three times daily "showed significantly better performance on memory and attention tests compared to placebo." It also notes a Clinical Nutrition trial in which "daily supplementation of 3 g creatine for one week reduced reports of mental fatigue in individuals after five nights of restricted sleep" and comments that these findings suggest creatine "can partially offset cognitive declines" and symptoms such as mental fatigue when sleep‑deprived.
Across randomized controlled trials of creatine in humans, outcomes are typically standardized neuropsychological tests (e.g., working memory, reaction time, reasoning) rather than subjective "brain fog" ratings. While meta‑analyses show small to moderate improvements in memory and certain attention or processing speed measures in some groups, especially under stress or in older adults, most trials do not directly ask participants about brain fog as a symptom. Therefore, any link between creatine and improvement in "brain fog" is usually inferred from objective cognitive improvements under conditions commonly associated with brain fog (such as sleep deprivation or aging), rather than directly measured as brain fog in trial endpoints.
This commercial blog article reviews multiple randomized controlled trials of creatine on cognition and frames the findings in terms of "brain fog." It claims that creatine "can help maintain brain function and performance, especially during stress and lack of sleep, which often cause brain fog" and that studies show creatine "can significantly improve short‑term memory and reasoning skills." The article cites systematic reviews indicating that creatine "notably improves short‑term memory, intelligence, and reasoning" and suggests that these effects might translate into improved mental clarity in people experiencing stress‑related or age‑related cognitive difficulties.
In this expert commentary video, biomedical scientist Rhonda Patrick summarizes human creatine cognition research, stating that creatine's brain benefits are most evident "in the background of stress," including aging, sleep deprivation, or neurodegenerative conditions. She notes that older adults seem to benefit from supplemental creatine and mentions a placebo‑controlled study in people with Alzheimer's disease given 20 g/day creatine, where cognitive function reportedly improved. She characterizes creatine as having potential cognitive benefits with relatively low downside, while acknowledging that evidence is strongest under conditions of brain stress rather than in all healthy young adults.
The episode claims creatine supplementation significantly improved cognitive performance, including processing speed and memory. This is a podcast discussion and not a primary study, so it is lower on the evidence hierarchy.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Multiple randomized trials and higher-level syntheses show creatine produces measurable improvements in cognitive domains that map directly onto what people commonly describe as “brain fog” (slowed thinking, poor attention, mental fatigue): a 2024 systematic review/meta-analysis of 16 RCTs found significant benefits for memory, attention time, and processing-speed time (Source 1, PubMed; Source 4, Frontiers), and controlled sleep-deprivation studies show creatine preserves attention/reaction time and improves mood/subjective fatigue under fatigue-like conditions (Source 3, PubMed; Source 6, Scientific Reports; Source 10, PubMed). Because “brain fog” is rarely a direct trial endpoint, the most scientifically grounded way to evaluate the claim is via these validated human cognitive and fatigue measures—and across independent RCTs in stressed/older groups plus mechanistic confirmation that supplementation raises brain creatine while improving complex task performance (Source 9, PubMed; Source 11, PubMed), the weight of evidence supports that creatine supplementation improves brain-fog–type symptoms in humans even if a regulatory review did not endorse a broad cognition claim at ≤3 g/day (Source 2, UKNHCC).
The Proponent commits a category error by equating improvements on standardized neuropsychological tests with relief from 'brain fog,' a subjective symptom construct — this inferential leap is precisely what Source 17 warns against, and no cited RCT validates it through direct patient-reported brain fog outcomes. Moreover, the Proponent's attempt to dismiss Source 2 (UKNHCC) as merely a dose-limited regulatory opinion ignores that the committee's conclusion — that no cause-and-effect relationship has been established between creatine and improved cognitive function — was reached after weighing the same body of RCT evidence the Proponent cites, and Source 1 itself confirms that no significant improvements were found for overall cognitive function or executive function, the very domains most central to the brain fog construct.
Argument against
The claim that creatine supplementation improves 'brain fog' in humans is fundamentally unsupported because, as Source 17 explicitly notes, no randomized controlled trials directly measure 'brain fog' as an endpoint — any purported link is merely inferred from objective cognitive test improvements, not from brain fog symptom ratings. Furthermore, Source 2 (UK Government UKNHCC), a highly authoritative regulatory body, concluded that 'a cause-and-effect relationship has not been established between the consumption of creatine and improved cognitive function,' and Source 1 found no significant improvements in overall cognitive function or executive function, undermining the broad claim that creatine reliably clears cognitive impairment in humans.
The Opponent commits a definitional fallacy by treating the absence of a trial endpoint literally labeled “brain fog” as disproof, even though the best-available human evidence necessarily operationalizes brain-fog–type complaints via validated measures of memory, attention/processing speed, mood, and subjective fatigue—and these show significant benefits in a 16-RCT meta-analysis (Source 1) and in controlled sleep-deprivation RCTs where creatine attenuates fatigue-related cognitive impairment (Sources 3, 6, 10). The Opponent also overgeneralizes the UKNHCC conclusion, which is explicitly limited to a specific low-dose claim (≤3 g/day) and does not negate higher-dose or stress-context effects demonstrated in RCTs (Sources 2, 6, 10), while misusing Source 1's null findings on “overall” cognition to ignore its statistically significant improvements in domains that most directly map onto “brain fog” (Source 1).
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
The claim that creatine 'improves brain fog in humans' contains a critical inferential gap: 'brain fog' is a subjective symptom construct that is never directly measured as a trial endpoint in any of the cited RCTs (Source 17 explicitly confirms this), meaning any logical chain from evidence to claim requires an inferential leap from objective neuropsychological test scores to a subjective symptom experience. The proponent's argument that validated cognitive measures 'map onto' brain fog is plausible but not logically equivalent — this is an indirect inference, not direct proof. However, the opponent's rebuttal overreaches by treating the absence of a 'brain fog' endpoint as disproof rather than as a gap in evidence; the UKNHCC conclusion (Source 2) is explicitly scoped to ≤3g/day doses and does not negate higher-dose RCT findings. The 2024 meta-analysis (Sources 1, 4) shows statistically significant improvements in memory, attention, and processing speed — domains genuinely associated with brain fog — and multiple sleep-deprivation RCTs (Sources 3, 6, 10) show creatine attenuates subjective fatigue and cognitive impairment under conditions that produce brain fog. The logical chain is: creatine raises brain creatine → improves performance on cognitive tasks associated with brain fog symptoms → therefore 'improves brain fog.' This chain is inferentially reasonable but not deductively tight, as the final link (objective test improvement = subjective brain fog relief) is assumed rather than demonstrated. The claim is therefore Misleading in its unqualified form — it overstates what the evidence directly proves while pointing toward something that is plausibly true in specific populations and conditions.
Expert 2 — The Context Analyst
The claim is framed as a direct clinical effect on “brain fog,” but the evidence pool largely measures specific neuropsychological domains (memory, attention, processing speed) and stress-context performance (sleep deprivation) rather than patient-reported brain fog, and effects appear heterogeneous by population, dose, and condition with null findings for overall cognition/executive function and a regulatory review not supporting a general cognition claim at ≤3 g/day [1][2][4][17]. With full context, it's plausible creatine can improve some cognitive facets that people may describe as brain-fog-like (especially under sleep deprivation/older age), but the dataset does not support the broad, symptom-level statement that creatine supplementation improves “brain fog” in humans as such, so the overall impression is misleading.
Expert 3 — The Source Auditor
High-authority systematic reviews and randomized controlled trials (Sources 1, 3, 4, and 6) demonstrate that creatine supplementation significantly improves memory, attention, processing speed, and mental fatigue, particularly under conditions of sleep deprivation or stress. While 'brain fog' is not a standardized clinical trial endpoint (Source 17), these objective improvements in its constituent cognitive domains mean the claim is mostly true, despite regulatory bodies noting a lack of established cause-and-effect for low daily doses (Source 2).